The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Original Article: Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis